Literature DB >> 12675197

Regulation of TH1/TH2 cytokine production by Chungsim-Yeunja-Tang in patients with cerebral infarction.

Hyun-Ja Jeong1, Sun-Yong Seo, Hyun-Soo Noh, Hye-Sun Park, Jong-Deok Lee, Kyung-Suk Kim, Kwang-Ho Cho, Kyung-Yo Kim, Hyung-Min Kim.   

Abstract

Chungsim-Yeunja-Tang is a prescription for the Taeumin cerebral infarction (CI) patients according to Sasang constitutional philosophy. Taeumin patients with CI were treated with CY-Tang during the acute stage. Clinical signs of CI disappeared markedly in about 2 weeks after oral administration of CY-Tang in all patients. The mean interleukin (IL)-2 plasma levels were slightly lower in the patients with CI than in the normal groups, whereas the mean TNF-alpha, IL-4, IL-6, and IgE levels were significantly higher in the patients with CI. There were no significant differences in interferon-gamma (IFN-gamma) levels between the groups. Serum IFN-gamma and IL-2 levels derived from (Th) 1 cells were significantly elevated in the patients with CI by CY-Tang administration. Significant reduced plasma levels of IL-4 and IL-6 derived from Th2 cells and IgE were observed in the patients treated with CY-Tang. Plasma levels TNF-alpha derived from Th1 significantly increased in the patients treated with CY-Tang. During the period of CY-Tang administration, there were no other adverse effects. The data indicate that CY-Tang has a good CI treatment effect, and that its action may be due to the regulation of cytokine production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675197     DOI: 10.1081/iph-120018281

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  1 in total

1.  Chungsim-Yeunja-Tang decreases the inflammatory response in peripheral blood mononuclear cells from patients with cerebral infarction through an NF-κB dependent mechanism.

Authors:  Hyun-Ja Jeong; In-Young Choi; Min-Ho Kim; Hyung-Min Kim; Phil-Dong Moon; Jin-Woo Hong; Soo-Hyun Kim
Journal:  J Neuroinflammation       Date:  2010-11-25       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.